Positron Emission Tomography (PET) produces images that illustrate body metabolism and other biological functions. PET reveals abnormalities that might otherwise go undetected by X-Ray, CT, MRI or Ultrasound. It is the most accurate imaging tool available in detecting the presence or spread of malignant tumors.

PET/CTi: a more complete picture.
National Medical Imaging now combines the strength of PET and CT taking cancer detection and treatment to a deeper level. PET detects metabolic changes while CT provides detail of anatomic structures. This powerful combination can determine exactly where a cancerous tumor is located, how far it has spread, and whether therapies in sue are performing as expected.

PET/CTi provides improved diagnostic ability in lung cancer, lymphoma, malignant melanoma and a variety of other gastrointestinal, gynecological and head and neck malignancies.

PET/CTi allows for:

• Superior localization of disease
• Reduced biopsy errors
• Enhanced surgical planning
• Accurate chemotherapy and radiation therapy planning
• Improved diagnostic confidence in patent management.

NMi's clinical team includes Board Certified Radiologists who have expertise in whole body PET as well as cross-sectional imaging. Cross-sectional imaging assists in the precise diagnosis as the correlation of these studies is imperative for accurate diagnosis.

Highly trained pre-certification specialists will consult closely with your office to obtain necessary insurance authorization, saving your office staff time and your patients the worry of high out of pocket expenses.

A new tool in cancer management.
For physicians and patients alike, PET offers a number of advantages in the management of cancer and other diseases. Specifically: Early detection of recurrent cancer and brain abnormalities such as Alzheimer's.

• Assessment of stage and location of tumor prior to surgery.
• Non-invasive monitoring of treatment success.
• Replaces multiple procedures with a single exam.
• Produces imaging information of superior quality.
• Can reduce or eliminate ineffective or unnecessary treatment.
• Validates and/or alters patient management and care.
• Safe and without risk of contrast reaction.

Clinical Applications